Anxin Wang1, Jie Xu1, Guojuan Chen1, David Wang1, S Claiborne Johnston1, Xia Meng1, Jinxi Lin1, Hao Li1, Yibin Cao1, Nan Zhang1, Caiyun Ma1, Liye Dai1, Xingquan Zhao1, Liping Liu1, Yongjun Wang1, Yilong Wang2. 1. From the Department of Neurology (A.W., J.X., X.M., J.L., H.L., N.Z., C.M., L.D., X.Z., L.L., Y.W., Y.W.), Beijing Tiantan Hospital, and Department of Epidemiology and Health Statistics (A.W.), School of Public Health, Capital Medical University; China National Clinical Research Center for Neurological Diseases (A.W., J.X., X.M., J.L., H.L., N.Z., C.M., L.D., X.Z., L.L., Y.W., Y.W.); Center of Stroke, Beijing Institute for Brain Disorders (A.W., J.X., X.M., J.L., H.L., N.Z., C.M., L.D., X.Z., L.L., Y.W., Y.W.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (A.W., J.X., X.M., J.L., H.L., N.Z., C.M., L.D., X.Z., L.L., Y.W., Y.W.); Department of Neurology (G.C., Y.C.), Tangshan Gongren Hospital, North China University of Science and Technology, Tangshan, China; INI Stroke Network (D.W.), OSF Healthcare System, University of Illinois College of Medicine, Peoria; and Dell Medical School (S.C.J.), University of Texas, Austin. 2. From the Department of Neurology (A.W., J.X., X.M., J.L., H.L., N.Z., C.M., L.D., X.Z., L.L., Y.W., Y.W.), Beijing Tiantan Hospital, and Department of Epidemiology and Health Statistics (A.W.), School of Public Health, Capital Medical University; China National Clinical Research Center for Neurological Diseases (A.W., J.X., X.M., J.L., H.L., N.Z., C.M., L.D., X.Z., L.L., Y.W., Y.W.); Center of Stroke, Beijing Institute for Brain Disorders (A.W., J.X., X.M., J.L., H.L., N.Z., C.M., L.D., X.Z., L.L., Y.W., Y.W.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (A.W., J.X., X.M., J.L., H.L., N.Z., C.M., L.D., X.Z., L.L., Y.W., Y.W.); Department of Neurology (G.C., Y.C.), Tangshan Gongren Hospital, North China University of Science and Technology, Tangshan, China; INI Stroke Network (D.W.), OSF Healthcare System, University of Illinois College of Medicine, Peoria; and Dell Medical School (S.C.J.), University of Texas, Austin. yilong528@gmail.com.
Abstract
OBJECTIVE: To investigate the association between oxidized low-density lipoprotein (oxLDL) and recurrent stroke in patients with minor stroke or TIA. METHODS: In the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial, baseline oxLDL levels were blindly measured in plasma with the 4E6 antibody in the core laboratory. The primary outcome was any stroke within 90 days. The secondary outcomes included any stroke within 1 year and ischemic stroke and combined vascular events within 90 days and 1 year. The associations of oxLDL with recurrent stroke were analyzed by Cox proportional hazards. RESULTS: Among 3,019 patients included in this study, the median (interquartile range) of oxLDL was 13.96 (6.65-28.81) μg/dL. After adjustment for conventional confounding factors, patients in the highest oxLDL quartile (≥28.81 μg/dL) had a higher risk of recurrent stroke within 90 days (hazard ratio 1.43, 95% confidence interval 1.03-1.98) compared to those in the lowest oxLDL quartile (<6.65 μg/dL). Similar results were found for secondary outcomes. We also found a J-shaped association between oxLDL and risk of each outcome. There were no significant interactions between oxLDL and low-density lipoprotein and use of dual antiplatelet, antihypertensive, antidiabetic, and statins agents. CONCLUSIONS: Elevated oxLDL levels can independently predict recurrent stroke in patients with minor stroke or TIA. CLINICALTRIALSGOV IDENTIFIER: NCT00979589.
RCT Entities:
OBJECTIVE: To investigate the association between oxidized low-density lipoprotein (oxLDL) and recurrent stroke in patients with minor stroke or TIA. METHODS: In the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial, baseline oxLDL levels were blindly measured in plasma with the 4E6 antibody in the core laboratory. The primary outcome was any stroke within 90 days. The secondary outcomes included any stroke within 1 year and ischemic stroke and combined vascular events within 90 days and 1 year. The associations of oxLDL with recurrent stroke were analyzed by Cox proportional hazards. RESULTS: Among 3,019 patients included in this study, the median (interquartile range) of oxLDL was 13.96 (6.65-28.81) μg/dL. After adjustment for conventional confounding factors, patients in the highest oxLDL quartile (≥28.81 μg/dL) had a higher risk of recurrent stroke within 90 days (hazard ratio 1.43, 95% confidence interval 1.03-1.98) compared to those in the lowest oxLDL quartile (<6.65 μg/dL). Similar results were found for secondary outcomes. We also found a J-shaped association between oxLDL and risk of each outcome. There were no significant interactions between oxLDL and low-density lipoprotein and use of dual antiplatelet, antihypertensive, antidiabetic, and statins agents. CONCLUSIONS: Elevated oxLDL levels can independently predict recurrent stroke in patients with minor stroke or TIA. CLINICALTRIALSGOV IDENTIFIER: NCT00979589.
Authors: Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2022-02-28